{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=24", "query": { "condition": "Phase I", "page": 24 }, "page_size": 10 }, "pagination": { "page": 24, "page_size": 10, "total_count": 18744, "total_pages": 1875, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=25&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+I&page=23&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-10T06:24:05.270Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01376453", "title": "Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Rectal Cancer" ], "interventions": [ { "name": "Sorafenib", "type": "DRUG" }, { "name": "5-Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2011-06", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2016-09-12", "last_synced_at": "2026-11-10T06:24:05.270Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01376453" }, { "nct_id": "NCT00004075", "title": "17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "tanespimycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-08", "completion_date": "2007-01", "has_results": false, "last_update_posted_date": "2011-08-03", "last_synced_at": "2026-11-10T06:24:05.270Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004075" }, { "nct_id": "NCT04603001", "title": "Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia (AML)", "Myelodysplastic Syndrome (MDS)", "Chronic Myelomonocytic Leukemia (CMML)", "Myeloproliferative Neoplasms (MPNs)" ], "interventions": [ { "name": "LY3410738", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2020-11-19", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-11-10T06:24:05.270Z", "location_count": 12, "location_summary": "Duarte, California • Los Angeles, California • Sacramento, California + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04603001" }, { "nct_id": "NCT01167166", "title": "Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Acute Myelocytic Leukemia", "Acute Lymphocytic Leukemia", "Myeloproliferative Disease", "Chronic Myeloid Leukemia" ], "interventions": [ { "name": "rigosertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Traws Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2010-07", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2017-06-26", "last_synced_at": "2026-11-10T06:24:05.270Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01167166" }, { "nct_id": "NCT06377566", "title": "A Study of BV-AVD in People With Bulky Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hodgkin Lymphoma" ], "interventions": [ { "name": "Brentuximab vedotin", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vinblastine", "type": "DRUG" }, { "name": "Dacarbazine", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "FDG-PET/CT scan", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2024-04-17", "completion_date": "2027-04", "has_results": false, "last_update_posted_date": "2026-04-23", "last_synced_at": "2026-11-10T06:24:05.270Z", "location_count": 8, "location_summary": "Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06377566" }, { "nct_id": "NCT02143466", "title": "AZD9291 in Combination With Ascending Doses of Novel Therapeutics", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Part A - AZD9291 in combination with AZD6094", "type": "DRUG" }, { "name": "Part A - AZD9291 in combination with continuous selumetinib (Asian subjects)", "type": "DRUG" }, { "name": "Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)", "type": "DRUG" }, { "name": "Part A - AZD9291 in combination with intermittent selumetinib", "type": "DRUG" }, { "name": "Part A - AZD9291 in combination with MEDI4736", "type": "DRUG" }, { "name": "Part B - AZD9291 in combination with AZD6094", "type": "DRUG" }, { "name": "Part B - AZD9291 in combination with selumetinib", "type": "DRUG" }, { "name": "Part B - AZD9291 in combination with MEDI4736", "type": "DRUG" }, { "name": "Part C - AZD6094 monotherapy (Japan only)", "type": "DRUG" }, { "name": "Part C - AZD9291 in combination with AZD6094 (Japan only)", "type": "DRUG" }, { "name": "Part D - AZD9291 in combination with AZD6094", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 344, "start_date": "2014-08-05", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-11-10T06:24:05.270Z", "location_count": 6, "location_summary": "Atlanta, Georgia • Boston, Massachusetts • New York, New York + 2 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02143466" }, { "nct_id": "NCT02628405", "title": "R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Recurrent Transformed Non-Hodgkin Lymphoma", "Refractory B-Cell Non-Hodgkin Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Refractory Transformed Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "Academic and Community Cancer Research United", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2016-05-20", "completion_date": "2025-12-20", "has_results": true, "last_update_posted_date": "2024-07-01", "last_synced_at": "2026-11-10T06:24:05.270Z", "location_count": 12, "location_summary": "Jacksonville, Florida • Urbana, Illinois • Iowa City, Iowa + 9 more", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Urbana", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Sioux City", "state": "Iowa" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02628405" }, { "nct_id": "NCT06895356", "title": "A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "Tavapadon", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 83, "start_date": "2025-03-26", "completion_date": "2025-06-16", "has_results": false, "last_update_posted_date": "2025-06-26", "last_synced_at": "2026-11-10T06:24:05.270Z", "location_count": 1, "location_summary": "Grayslake, Illinois", "locations": [ { "city": "Grayslake", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06895356" }, { "nct_id": "NCT03063645", "title": "Study to Compare the Pharmacokinetics of AC 1202 and Two Doses of AC-SD-01 on Ketone Body Production", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "AC-1202", "type": "DRUG" }, { "name": "AC-SD-01 (50 g)", "type": "DRUG" }, { "name": "AC-SD-01 (75 g)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cerecin", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "19 Years to 55 Years · Male only" }, "enrollment_count": 17, "start_date": "2017-03-11", "completion_date": "2017-05-05", "has_results": false, "last_update_posted_date": "2017-06-27", "last_synced_at": "2026-11-10T06:24:05.270Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT03063645" }, { "nct_id": "NCT06153095", "title": "A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Systemic Lupus Erythematosus", "Lupus Nephritis" ], "interventions": [ { "name": "IMPT-514", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Lyell Immunopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2024-02-15", "completion_date": "2025-01-09", "has_results": false, "last_update_posted_date": "2025-02-10", "last_synced_at": "2026-11-10T06:24:05.270Z", "location_count": 3, "location_summary": "Los Angeles, California • San Francisco, California • Iowa City, Iowa", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT06153095" } ] }